 |
|
Anti–Vascular Endothelial Growth Factor Bevacizumab (Avastin) for Radiation Retinopathy
Paul T. Finger, MD;
Kimberly Chin, OD
Arch Ophthalmol. 2007;125(6):751-756.
Objective To evaluate intravitreal bevacizumab for radiation retinopathy.
Methods After plaque radiation therapy, 6 patients developed radiation retinopathy (retinal edema, hemorrhages, microangiopathy, and neovascularization). Intravitreal bevacizumab (1.25 mg in 0.05 mL) was periodically injected (every 6-8 weeks). Ophthalmic evaluations included visual acuity, ophthalmic examination, fundus photography, fluorescein angiography, and optical coherence tomography/scanning laser ophthalmoscopy (OCT/SLO) imaging.
Results No bevacizumab-related ocular or systemic adverse effects have occurred within the first 8 months of therapy. Progressive reductions in retinal hemorrhages, exudates, cotton-wool spots, and microangiopathy were documented by photography, angiography, and OCT/SLO imaging. Decreased macular edema was the most common finding. Improvement or stabilization of visual acuity was noted in all cases.
Conclusions Intravitreal bevacizumab was tolerated, improved or maintained vision, and reduced hemorrhage and retinal edema (angiographic leakage). This study should lead to additional and longer-term studies of humanized monoclonal anti–vascular endothelial growth factor antibody therapy for radiation retinopathy.
Author Affiliations: The New York Eye Cancer Center, New York (Drs Finger and Chin), and The New York Eye and Ear Infirmary, New York (Dr Finger).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Stereotactic radiotherapy for treatment of juxtapapillary choroidal melanoma: 3-year follow-up
Krema et al.
Br J Ophthalmol 2009;93:1172-1176.
ABSTRACT
| FULL TEXT
|
